

Data Sharing Statement

Ma. Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor–Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination. *JAMA Oncol.* Published January 18, 2024.
doi:10.1001/jamaoncol.2023.6038

Data

Data available: Yes

Data types: Deidentified participant data

How to access data: NCTN/NCORP Data Archive (<https://nctn-data-archive.nci.nih.gov/>)

When available: beginning date: 01-01-2024

Supporting Documents

Document types: None

Additional Information

Who can access the data: Anyone requesting data will go through a formal review process including verifying the availability of data, conducting a review of any existing agreements that may have implications for the project, and ensuring that any transfer is in compliance with the IRB.

Types of analyses: Upon formal review of request data will be made available for any purpose.

Mechanisms of data availability: Data will be made available with a signed data access agreement.